Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Veracyte (VCYT) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Veracyte (VCYT) over the last 14 years, with Q3 2025 value amounting to 17.4%.

  • Veracyte's EBIT Margin rose 70300.0% to 17.4% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.0%, marking a year-over-year increase of 105300.0%. This contributed to the annual value of 3.62% for FY2024, which is 273800.0% up from last year.
  • As of Q3 2025, Veracyte's EBIT Margin stood at 17.4%, which was up 70300.0% from 4.05% recorded in Q2 2025.
  • In the past 5 years, Veracyte's EBIT Margin registered a high of 17.4% during Q3 2025, and its lowest value of 123.74% during Q1 2021.
  • For the 5-year period, Veracyte's EBIT Margin averaged around 16.0%, with its median value being 12.74% (2023).
  • As far as peak fluctuations go, Veracyte's EBIT Margin tumbled by -845400bps in 2021, and later soared by 1012400bps in 2022.
  • Veracyte's EBIT Margin (Quarter) stood at 18.32% in 2021, then skyrocketed by 63bps to 6.75% in 2022, then tumbled by -436bps to 36.16% in 2023, then skyrocketed by 110bps to 3.52% in 2024, then skyrocketed by 394bps to 17.4% in 2025.
  • Its EBIT Margin was 17.4% in Q3 2025, compared to 4.05% in Q2 2025 and 2.54% in Q1 2025.